Daiichi Sankyo and AstraZeneca's ENHERTU has been conditionally approved by China's National Medical Products Administration (NMPA) as a single agent for adult patients with a specific type of non ...

In February, AstraZeneca and Daiichi Sankyo teased the results of their pivotal trial of Enhertu in HER2-low breast cancer, and, at ASCO, they finally revealed the data – with the numbers every ...

Lola McEvoy is set to press the government upon the use of Enhertu after the death of Heather Sawyer - a Darlington grandmother who campaigned for the drug she believed would have extended her life.

NICE has rejected the use of AstraZeneca and Daiichi Sankyo’s Enhertu as an NHS treatment for advanced HER2-low breast cancer, a decision that the companies have described as “devastating”.

The drug, called Enhertu, can give patients with a specific type of incurable breast cancer an extra six months to live on average. The health assessment body, NICE, is the only organisation ...

ENHERTU is indicated for patients with unresectable or metastatic NSCLC with activating HER2 mutations who have previously undergone systemic therapy. Credit: Nemes Laszlo/Shutterstock. Daiichi Sankyo ...

UK pharma major AstraZeneca (LSE: AZN) and Japanese drugmaker Daiichi Sankyo’s (TYO: 4568) Enhertu (trastuzumab deruxtecan) has won conditional approval in China as a monotherapy for the treatment of ...

New research shows that ENHERTU (trastuzumab deruxtecan) could change the standard of care treatment for metastatic HER2 positive breast cancer patients. The trial compared ENHERTU and Kadcyla, the ...

The Supporting Information is available free of charge at https://pubs.acs.org/doi/10.1021/acs.jmedchem.4c01113. PDB files of synthesized photopeptides in complex ...

The FDA approved the first treatment for MASH in March this year. Image credit: Shutterstock/ Iurii Motov. Inventiva has secured up to €348m ($380m) in financing to help wrap up a Phase III trial for ...